Flexion Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of anti-inflammatory and analgesic therapies for the treatment of patients with musculoskeletal conditions. It lead product candidate includes Zilretta, an intra-articular injection for the management of osteoarthritis (OA) pain of the knee. The company also develops FX101 and FX201, which is a pre-clinical stage programs for the treatment OA of large joints. The company was founded in 2007 and is headquartered in Burlington, Massachusetts.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:FLXN
CUSIPN/A
Phone781-305-7777
Debt
Debt-to-Equity Ratio0.80
Current Ratio12.90
Quick Ratio12.78
Price-To-Earnings
Trailing P/E Ratio-5.26
Forward P/E Ratio-4.62
P/E GrowthN/A
Sales & Book Value
Annual Sales$350,000.00
Price / Sales2,369.69
Cash FlowN/A
Price / CashN/A
Book Value$6.93 per share
Price / Book3.16
Profitability
EPS (Most Recent Fiscal Year)($4.16)
Net Income$-137,480,000.00
Net MarginsN/A
Return on Equity-80.84%
Return on Assets-43.87%
Miscellaneous
Employees251
Outstanding Shares37,820,000
Market Cap$868.25 million
Flexion Therapeutics (NASDAQ:FLXN) Frequently Asked Questions
What is Flexion Therapeutics' stock symbol?
Flexion Therapeutics trades on the NASDAQ under the ticker symbol "FLXN."
How were Flexion Therapeutics' earnings last quarter?
Flexion Therapeutics Inc (NASDAQ:FLXN) posted its quarterly earnings results on Tuesday, August, 7th. The specialty pharmaceutical company reported ($1.16) earnings per share for the quarter, topping the Zacks' consensus estimate of ($1.22) by $0.06. The specialty pharmaceutical company had revenue of $3.80 million for the quarter, compared to analysts' expectations of $3.96 million. View Flexion Therapeutics' Earnings History.
When is Flexion Therapeutics' next earnings date?
What price target have analysts set for FLXN?
9 analysts have issued twelve-month target prices for Flexion Therapeutics' shares. Their forecasts range from $36.00 to $570.00. On average, they anticipate Flexion Therapeutics' stock price to reach $98.8889 in the next year. This suggests a possible upside of 350.9% from the stock's current price. View Analyst Price Targets for Flexion Therapeutics.
What is the consensus analysts' recommendation for Flexion Therapeutics?
9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Flexion Therapeutics in the last year. There are currently 1 hold rating and 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Flexion Therapeutics.
Are investors shorting Flexion Therapeutics?
Flexion Therapeutics saw a decrease in short interest in July. As of July 31st, there was short interest totalling 10,518,815 shares, a decrease of 3.7% from the July 13th total of 10,922,687 shares. Based on an average trading volume of 387,639 shares, the days-to-cover ratio is presently 27.1 days. Approximately 33.3% of the shares of the company are short sold. View Flexion Therapeutics' Current Options Chain.
Who are some of Flexion Therapeutics' key competitors?
Some companies that are related to Flexion Therapeutics include Intercept Pharmaceuticals (ICPT), Evotec (EVTCY), Array Biopharma (ARRY), Opko Health (OPK), Blueprint Medicines (BPMC), Heron Therapeutics (HRTX), Akcea Therapeutics (AKCA), Amicus Therapeutics (FOLD), Ironwood Pharmaceuticals (IRWD), The Medicines (MDCO), Ascendis Pharma A/S (ASND), Emergent Biosolutions (EBS), Mallinckrodt (MNK), Supernus Pharmaceuticals (SUPN) and Global Blood Therapeutics (GBT).
Who are Flexion Therapeutics' key executives?
Flexion Therapeutics' management team includes the folowing people:
- Dr. Michael D. Clayman, Co-Founder, Pres, CEO & Director (Age 66)
- Dr. Neil Bodick, Co-Founder & Chief Scientific Officer (Age 71)
- Mr. Mark S. Levine, Gen. Counsel & Sec. (Age 45)
- Mr. David A. Arkowitz, Chief Financial Officer (Age 57)
- Scott Young, VP of Corp. Communications & Investor Relations
Has Flexion Therapeutics been receiving favorable news coverage?
Media stories about FLXN stock have been trending somewhat positive on Friday, Accern reports. The research group scores the sentiment of news coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Flexion Therapeutics earned a coverage optimism score of 0.14 on Accern's scale. They also gave press coverage about the specialty pharmaceutical company an impact score of 49.50 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the next few days. View Recent Headlines for Flexion Therapeutics.
Who are Flexion Therapeutics' major shareholders?
Flexion Therapeutics' stock is owned by many different of retail and institutional investors. Top institutional shareholders include Gilder Gagnon Howe & Co. LLC (9.17%), BlackRock Inc. (7.52%), Miller Value Partners LLC (7.02%), Peregrine Capital Management LLC (1.77%), Wasatch Advisors Inc. (1.72%) and Ardsley Advisory Partners (1.57%). Company insiders that own Flexion Therapeutics stock include David Arkowitz, Frederick W Driscoll, Mark Stejbach, Michael D Clayman, Neil Bodick, Samuel D Colella and Yamo Deniz. View Institutional Ownership Trends for Flexion Therapeutics.
Which major investors are selling Flexion Therapeutics stock?
FLXN stock was sold by a variety of institutional investors in the last quarter, including Gilder Gagnon Howe & Co. LLC, Raymond James & Associates, Miller Value Partners LLC, BB&T Securities LLC, Alps Advisors Inc., Alps Advisors Inc., California Public Employees Retirement System and Raymond James Financial Services Advisors Inc.. View Insider Buying and Selling for Flexion Therapeutics.
Which major investors are buying Flexion Therapeutics stock?
FLXN stock was acquired by a variety of institutional investors in the last quarter, including Artisan Partners Limited Partnership, Zweig DiMenna Associates LLC, BlackRock Inc., Clearline Capital LP, Castleark Management LLC, Ardsley Advisory Partners, Bank of America Corp DE and Gagnon Securities LLC. Company insiders that have bought Flexion Therapeutics stock in the last two years include David Arkowitz, Mark Stejbach, Michael D Clayman, Neil Bodick, Samuel D Colella and Yamo Deniz. View Insider Buying and Selling for Flexion Therapeutics.
How do I buy shares of Flexion Therapeutics?
Shares of FLXN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Flexion Therapeutics' stock price today?
One share of FLXN stock can currently be purchased for approximately $21.93.
How big of a company is Flexion Therapeutics?
Flexion Therapeutics has a market capitalization of $868.25 million and generates $350,000.00 in revenue each year. The specialty pharmaceutical company earns $-137,480,000.00 in net income (profit) each year or ($4.16) on an earnings per share basis. Flexion Therapeutics employs 251 workers across the globe.
How can I contact Flexion Therapeutics?
Flexion Therapeutics' mailing address is 10 MALL ROAD SUITE 301, BURLINGTON MA, 01803. The specialty pharmaceutical company can be reached via phone at 781-305-7777 or via email at [email protected]
MarketBeat Community Rating for Flexion Therapeutics (NASDAQ FLXN)
MarketBeat's community ratings are surveys of what our community members think about Flexion Therapeutics and other stocks. Vote "Outperform" if you believe FLXN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe FLXN will underperform the S&P 500 over the long term. You may vote once every thirty days.
